Decentralised Phase 3 Dermatology Case Study

Case Study Introduction

A global pharmaceutical company conducting advanced clinical development in dermatology initiated a large scale Phase 3 long-term extension (LTE) study to evaluate the prolonged safety, efficacy and immunogenicity of a targeted biologic therapy for moderate-to-severe atopic dermatitis (AD).

The study followed participants from multiple preceding Phase 2 and Phase 3 trials and was designed to generate long-term clinical evidence in a chronic disease setting. Due to its duration, scale, and reliance on decentralised patient participation, the trial presented significant scientific and technological complexity, requiring a highly specialised clinical data management partner.

Quanticate was selected to provide bespoke clinical data management solutions to support the successful execution of this study.

Objectives and Key Challenges

Several key challenges were identified at the outset:

Long-term uncertainty around sustained safety and efficacy of targeted biologic therapy in a chronic dermatological condition
The need to evaluate continuous treatment versus treatment interruption and re-initiation, reflecting real-world clinical use
Reliance on home-based administration and patient-reported outcomes, introducing adherence and monitoring challenges, data completeness and consistency of safety and efficacy reporting over an extended duration.
Integration of legacy data from multiple earlier-phase trials to support longitudinal analysis

Need support with long-term clinical trial reporting in dermatology studies?

Discover how our specialists can help you manage decentralised data collection, maintain data integrity, and support confident long-term study oversight. Contact us today for a custom solution.

Request a Consultation

Strategic Approach and Tailored Solutions

To address the challenges and ensure the success of the study, Quanticate implemented an innovative clinical data management strategy aligned to the study’s design and long-term objectives, including:

Support for both continuous treatment and treatment interruption with re-initiation cohorts, enabling direct evaluation of safety, sustained efficacy, and immunogenicity under conditions reflective of real-world clinical practice
Data infrastructure configured to support home-based administration and decentralised participation, reducing patient burden while maintaining oversight in a chronic disease setting
Implementation of customised electronic data capture (EDC) and electronic patient-reported outcome (ePRO) systems, designed to manage extended-duration, decentralised data collection

Integrated real-time data availability, monitoring, adherence oversight, validation, and statistical quality control, enabling timely identification of safety signals, ensuring consistent data quality across global study sites, and preserving data integrity for regulatory analysis
Bespoke clinical data management systems tailored to long-duration studies, capable of supporting protocol amendments and evolving study requirements over the trial lifecycle
Seamless integration of legacy data from multiple prior Phase 2 and Phase 3 studies, preserving longitudinal continuity across the broader clinical programme

Successful Client Outcomes

With the support of Quanticate, the sponsor was successfully with their study, overcoming the inherent challenges of extended-duration, decentralised clinical research and generating high-quality longitudinal data suitable for regulatory submission and long-term safety evaluation.

Key outcomes included:

Reliable generation of safety, efficacy, and immunogenicity evidence in a chronic disease population
High levels of data completeness and consistency across global sites over an extended study duration, supporting regulatory-grade longitudinal analysis
Effective support for decentralised trial participation, improving patient adherence and reducing operational burden
Successful integration and preservation of longitudinal data across multiple clinical trial phases, ensuring continuity of evidence
Enhanced confidence in study outcomes through robust, real-time data oversight and sustained data integrity

Conclusion

By enabling sustained data integrity, real-time oversight, and continuity across multiple trial phases, Quanticate’s solutions directly addressed the unique scientific and technological challenges associated with long-term extension studies of biologic therapies. The bespoke systems and processes developed to support non-standard, long-duration trial requirements were critical to the successful evaluation of long-term biologic therapy and represent a clear example of Quanticate’s research and development capabilities in complex clinical data management.

Clinical Data Management for a Decentralised Phase 3 Dermatology Study